Figure 1.

A schematic of DCM. (a) The first step includes: (i) Functionalizing the MNPs with antibody I; (ii) Mixing the functionalized MNPs (carrying antibody I) with the sample to capture the target cells. (b) The second step includes introducing the mixture of blood sample and MNPs to the microfluidic chip and capturing the MNPs-cells to binds to the antibody II on the gold nanoslits. The cell binding on the gold nanoslits was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits. The detection area of the nanoslits is defined by the focal spot of the probe light.